Patient‐derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management

Abstract

These results provide evidence that PLC-PDX preclinical platform can strongly contribute to accelerate the identification and diversification of anticancer treatment for aggressive subtypes of pediatric liver cancer. (Hepatology 2016;64:1121-1135).